A SPECIAL PUBLICATION FOR MEMBERS OF THE CANCER INSTITUTE OF NEW JERSEY NETWORK

Cooper University Hospital Offers CyberKnife Technology for Cancer Treatments

Camden, NJ – Cooper University Hospital is now offering a ground breaking cancer treatment tool. CyberKnife technology, one of the most advanced options in radiosurgery treatment for cancer patients is the first and only radiosurgery system designed to pinpoint and destroy tumors anywhere in the body. The addition of the new CyberKnife facility, located in Mount Laurel, N.J., makes Cooper the only hospital in the Delaware Valley to have both CyberKnife and Gamma Knife radiosurgery devices.  These complementary technologies use highly accurate (sub-millimeter) beams of radiation to destroy cancer cells. These technologies are being used at Cooper to treat cancers of the brain, spine, lung, liver, pancreas and prostate. The CyberKnife is a precise, painless, non-invasive radiation treatment that can be an alternative to conventional surgery for patients with tumors considered inoperative or difficult to remove. The CyberKnife may also be used to treat patients who have been previously exposed to the maximum allowable dose of radiation but require further treatment.

CINJOG Announces New Clinical Research Associate

New Brunswick, NJ – Mr. Martin Kleber recently joined CINJ as the new Clinical Research Associate for The Cancer Institute of New Jersey Oncology Group (CINJOG).   In this capacity, Martin will be responsible for the initiation and coordination of all CINJOG initiated studies at CINJ Network institutions.  Martin's duties include monitoring clinical data to ensure investigator and site compliance with the study protocol, and to assure the protection of rights, safety and well being of human study subjects.    Martin will function as a valuable resource person for the research staff at our Network hospitals and support the day-to-day research operations.   Martin will also be actively participating in ongoing quality assurance activities such as training, orientation and precepting of CINJOG research staff in the CINJ Network hospitals.   Martin joins CINJOG from Memorial Sloan-Kettering Cancer Center where he served as a Research Manager in the department of Neuro-oncology.    He holds a BA in Communications from Seton Hall University and a MS from Iona College.  Martin is well published and has exceptional presentation skills.   Martin can be reached at 732-235-9430.

Centralized IRB Process Available for CINJOG Member Hospitals

New Brunswick, NJ - The Cancer Institute of New Jersey is pleased to announce that a new Centralized IRB process is now available to all CINJ Oncology Group (CINJOG) member hospitals for CINJOG clinical trials. A template letter of request is available for hospital IRB Chairmen to complete to formally apply for UMDNJ Central IRB review.  Interested hospitals should contact Linda Hassett (joannili@umdnj.edu) at 732-235-7569.